局部晚期宫颈癌女性中磁共振引导与计算机断层扫描引导高剂量率组织间近距离放疗的结局比较
2005至2015年间56例局部晚期宫颈癌患者接受高剂量率组织间近距离放疗,其中29例磁共振引导、27例计算机断层扫描引导,磁共振组患者为前瞻性II期临床试验入组。中位随访磁共振组19.7个月、计算机断层扫描组18.4个月,两组2年局部控制率分别为96%和87%(时序检验P=0.65),磁共振组2年总生存率显著更优(84%对56%,P=0.036),毒性无差异。
要点
- 磁共振引导与计算机断层扫描引导的2年局部控制率分别为96%和87%,差异无统计学意义(P=0.65)。
- 磁共振引导组2年总生存率显著优于计算机断层扫描引导组(84%对56%,P=0.036)。
- 两组高危临床靶体积及危及器官中位累积剂量、毒性均无统计学显著差异。
核心结论
- 在局部晚期宫颈癌患者中,磁共振引导高剂量率组织间近距离放疗的2年局部控制率估计为96%,生存率和毒性结局良好。
研究设计与样本
- 2005至2015年间共56例局部晚期宫颈癌患者接受高剂量率组织间近距离放疗,其中磁共振引导组29例、计算机断层扫描引导组27例;磁共振组患者为前瞻性II期临床试验入组;数据分析采用Kaplan-Meier法和Cox比例风险模型(JMP®和R®软件)。
主要发现
- 中位随访时间磁共振组为19.7个月、计算机断层扫描组为18.4个月。
- 两组在诊断时年龄、组织学、肿瘤大小>4cm比例、分级、FIGO分期或淋巴结受累方面无统计学显著差异;磁共振组淋巴血管受累多于计算机断层扫描组(p<0.01)。
- 评估计划时,高危临床靶体积及危及器官的中位累积剂量无统计学显著差异。
- 2年Kaplan-Meier局部控制率磁共振引导组为96%、计算机断层扫描引导组为87%(时序检验p=0.65)。
- 2年总生存率磁共振引导组为84%、计算机断层扫描引导组为56%,磁共振引导组显著更优(p=0.036)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose was to compare local control (LC), overall survival (OS) and dose to the organs at risk (OAR) in women with locally advanced cervical cancer treated with MR-guided versus CT-guided interstitial brachytherapy (BT). METHODS: 56 patients (29 MR, 27 CT) were treated with high-dose-rate (HDR) interstitial BT between 2005-2015. The MR patients had been prospectively enrolled on a Phase II clinical trial. Data were analyzed using Kaplan-Meier (K-M) and Cox proportional hazards statistical modeling in JMP® & R®. RESULTS: Median follow-up time was 19.7months (MR group) and 18.4months (CT group). There were no statistically significant differences in patient age at diagnosis, histology, percent with tumor size >4cm, grade, FIGO stage or lymph node involvement between the groups. Patients in the MR group had more lymphovascular involvement compared to patients in the CT group (p<0.01). When evaluating plans generated, there were no statistically significant differences in median cumulative dose to the high-risk clinical target volume or the OAR. 2-year K-M LC rates for MR-based and CT-based treatments were 96% and 87%, respectively (log-rank p=0.65). At 2years, OS was significantly better in the MR-guided cohort (84% vs. 56%, p=0.036). On multivariate analysis, squamous histology was associated with longer OS (HR 0.23, 95% CI 0.07-0.72) in a model with MR BT (HR 0.35, 95% CI 0.08-1.18). There was no difference in toxicities between CT and MR BT. CONCLUSION: In this population of locally advanced cervical-cancer patients, MR-guided HDR BT resulted in estimated 96% 2-year local control and excellent survival and toxicity rates.
引用
- Kamran SC, Manuel MM, Cho LP, et al. Comparison of outcomes for MR-guided versus CT-guided high-dose-rate interstitial brachytherapy in women with locally advanced carcinoma of the cervix. Gynecol Oncol. 2017. PMID: 28318644. doi:10.1016/j.ygyno.2017.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。